Key Developments For Clinical Data Inc
Clinical Data Inc (CLDA.O) (Consolidated Issue listed on NASDAQ Global Market)
Clinical Data, Inc. Initiates Phase III Trial of Stedivaze for Cardiac Stress Testing
Clinical Data, Inc. announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart. The Phase III trial will also compare the tolerability of Stedivaze to adenosine, a standard pharmacologic stress agent used in MPI scans.
Clinical Data, Inc.'s PGxHealth Launches Genetic Test For Dilated Cardiomyopathy
PGxHealth, a division of Clinical Data, Inc., announced the launch of its genetic test for familial Dilated Cardiomyopathy, an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death. The introduction of the FAMILION DCM Test at the 2009 American Heart Association meeting, November 14-17 in Orlando, FL, marks the third significant genetic test launched by PGxHealth over the past 18 months.
Clinical Data, Inc. Prices Public Offering Of Common Stock
Clinical Data, Inc. announced that it has raised gross proceeds of approximately $47.4 million through the public offering of 2,750,000 newly issued shares of its common stock at a price of $17.25 per share. All of the shares are being offered by Clinical Data, Inc. The underwriters have an option to purchase up to an additional 412,500 shares to cover over-allotments, which, if purchased, would result in total gross proceeds to the Company of approximately $54.6 million. The offering is expected to close no later than November 2, 2009. Piper Jaffray & Co. is acting as the sole book running manager.
Clinical Data, Inc. Announces Public Offering of Common Stock
Clinical Data, Inc. announced that it intends to offer shares of common stock in an underwritten public offering. Piper Jaffray & Co. is acting as the sole book running manager. The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission.
Clinical Data, Inc. Sells Certain Non Core Assets To Intrexon Corporation
Clinical Data, Inc. announced the sale of certain assets to Intrexon Corporation. Under the asset purchase agreement, Intrexon will assume certain liabilities and pay Clinical Data $1.5 million in cash to acquire substantially all the property and equipment situated in Avalon Pharmaceuticals' Germantown, MD facility, while Clinical Data will retain all intellectual property rights acquired in the Avalon acquisition, including all rights to a promising oncology drug candidate targeting the beta-catenin pathway and the AvalonRX biomarker discovery platform. As part of the purchase agreement, Clinical Data will sublease from Intrexon a portion of the laboratory space and offices that are directly associated with Clinical Data's oncology program, which includes the lead beta-catenin compound.
